Press Releases

March 8, 2019
- Results from the ALLEVIATE Phase 3 Clinical Trial in Allergic Conjunctivitis Expected in Early 2019 - The RENEW Adaptive Phase 3 Clinical Trial in Dry Eye Disease Expected to Begin in First Half of 2019 - Results from the SOLACE Phase 3 Clinical Trial in Noninfectious Anterior Uveitis Expected in ...
February 12, 2019
LEXINGTON, Mass. , Feb. 12, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a ...